varoglutamstat
Diabetic Kidney Disease
Phase 2Active
Key Facts
About Vivoryon Therapeutics
Vivoryon Therapeutics is a clinical-stage biotech company based in Halle, Germany, with a 25+ year history. The company is developing innovative small molecule drugs, primarily targeting diabetic kidney disease (DKD) with its lead candidate, varoglutamstat, a first-in-class QPCT/L inhibitor. Under the leadership of CEO/CMO Dr. Frank Weber, Vivoryon is pursuing a precision medicine strategy in a large, underserved market with significant unmet need. The company's success hinges on the clinical and regulatory progress of its lead asset.
View full company profileTherapeutic Areas
Other Diabetic Kidney Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Pirfenidone | Gyre Therapeutics | Phase 1 |